Colorectal Cancer

Management of Metastatic Colon Cancer

Considering data from the real-world setting is becoming increasingly important with the use of anticancer agents, as there is likely a big difference between patients in a clinical trial and patients in the real world, said Juan Manuel O’Connor, MD. During the 2018 ESMO Congress, O'Connor presented real-world dosing findings for regorafenib in patients with metastatic colorectal cancer.

During a presentation at the 2018 International Society of Gastrointestinal Oncology Annual Meeting,&nbsp;Dustin Deming, MD, discussed treatment options showing promise for patients with&nbsp;<em>BRAF</em> V600E&ndash;mutant metastatic colorectal cancer.

Anthony F. Shields, MD, PhD, discusses pivotal data from the IDEA pooled analysis, consisting of 6 international, noninferiority, phase III colon cancer studies.

Al B. Benson III, MD, FACP, FASCO,&nbsp;discusses the treatment landscape for advanced and metastatic CRC and how molecular profiling can play a vital role in selecting the optimal treatment plan for each patient. He also emphasizes the importance of participation in clinical trials to further understand these patients.

Hendrik-Tobias Arkenau, MD, PhD, discusses the rationale for using TAS-102 (trifluridine/tipiracil; Lonsurf) as a treatment for patients with gastric cancers.

James L. Wade III, MD, FACP, FASCO, discusses the importance of clinical trials in the community.

Colorectal Cancer

I think one of the most important advancements in biomedical technology that has improved our understanding of the complexities of cancer is the ability to sequence the cancer genome for any individual patient, in a rapid and cost-effective manner, to help us make treatment decisions in the clinic.

Groundbreaking developments in cancer therapies can change lives, extending survival and sending patients who previously thought their chances were slim into remission. But these therapies come at a cost, and many patients reel at the prospect of heavy financial burdens. To help patients and programs meet the challenges of affording cancer treatments, community cancer centers are expanding the role of financial advocates in their organizations.